Skip to main content
. 2004 Jun 22;91(2):344–354. doi: 10.1038/sj.bjc.6601975

Table 5. Joint association of XPD-751, ERCC1-118, TS-3′UTR, and GSTP1-105 polymorphisms with survival and time to progression after 5-FU/oxaliplatin chemotherapy for disseminated colorectal cancer (multivariable analysis, stratified by ECOG).

    Survival
Progression
Factors No. of patients Adj. relative riska Adj. P-valuea Adj. relative riskb Adj. P-valueb
XPD-751     0.037    
 Lys/Lys 40 1      
 Lys/Gln 53 1.50 (0.79, 2.87)      
 Gln/Gln 13 3.33 (1.39, 7.99)      
           
ERCC1-118     0.037    
 Favourable: C/C 30 1      
 Unfavourable 76 2.05 (1.00, 4.20)      
           
TS-3′UTR     0.091   0.020
 Favourable: +6BP/+6BP 37 1   1  
 Unfavourable 65 1.65 (0.91, 2.99)   1.76 (1.08, 2.86)  
 Unknown 4        
           
GSTP1-105     0.072   0.018
 Val/Val 10 1   1  
 Ile/Val 47 2.73 (0.88, 8.45)   0.96 (0.42, 2.21)  
 Ile/Ile 49 3.25 (1.04, 10.16)   2.00 (0.85, 4.71)  

5-FU=5-fluorouracil; CI=confidence interval; GSTP=glutathione S-transferase; TS=thymidylate synthase; UTR=untranslated region.

a

Based on Cox's proportional-hazards model, stratified by ECOG, with all four genes included for survival.

b

Based on Cox's proportional-hazards model, stratified by ECOG, with TS-3′UTR and GSTP1-105 for time to progression.